Want to see GB:FAB full AI Analyst Report?
FAB Stock Chart & Stats
11.25 p
0.65 p(6.05%)
At close: 4:00 PM EDT
11.25 p
0.65 p(6.05%)
Day’s Range― - ―
52-Week Range4.70 p - 20.00 p
Previous CloseN/A
Volume23.22K
Average Volume (3M)673.76K
Market Cap
£7.51M
Enterprise Value13.92M
Total Cash (Recent Filing)£1.04M
Total Debt (Recent Filing)£331.00K
Price to Earnings (P/E)―
Beta-0.75
Next Earnings
Dec 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,156,876
10 Day Avg. Volume1,076,976
30 Day Avg. Volume673,761
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)8.89
Price to Sales (P/S)6.83
P/FCF Ratio-12.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.10M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong 2026 revenue rebound indicates renewed demand for Fusion Antibodies’ antibody discovery and development services. If sustained, higher project activity can improve operating leverage, strengthen customer traction, and provide a larger base from which the company can pursue scale over the next several quarters.
Gross Margin ImprovementA materially higher gross margin suggests the recent revenue mix or delivery economics were more favorable than in prior periods. Maintaining this improvement would increase the contribution available to fund research operations, reduce the burden of fixed costs, and support a path toward better underlying profitability.
Contained LeverageContained leverage gives Fusion Antibodies more financial flexibility than a heavily debt-funded business and limits immediate pressure from borrowing obligations. The larger equity base also supports its asset base, leaving more capacity to manage ongoing development activity while profitability and cash generation remain under improvement.
Bears Say
Persistent LossesSevere operating and net losses show that the recent revenue recovery has not yet translated into sustainable earnings. Continued losses can constrain reinvestment, weaken equity returns, and make the company more dependent on financing while it seeks sufficient scale to cover its operating cost base.
Ongoing Cash BurnNegative operating and free cash flow means the business is not currently funding its activities internally. Although cash burn improved versus earlier periods, continued reliance on external funding can reduce financial flexibility and may require additional capital before operations become self-sustaining.
Volatile Revenue And ScaleThe multi-year revenue volatility indicates that demand has not yet developed into a consistently expanding base of project work. Without more stable scale, margins and cash generation may remain sensitive to changes in customer activity, delaying the transition from specialist service provider to durable profitable platform.
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 4.70 p and its highest was 20.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £7.51M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Dec 07, 2026 which is in 48 days.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Sep 14, 2026. The company reported -0.005 p earnings per share for the quarter.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,156,876 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report. Following the earnings report the stock price went down -21.277%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fusion Antibodies Plc
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Scancell Holdings
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―